Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of AT9283 given as a 24 hour infusion on days 1 and 8 every three weeks in patients with advanced incurable malignancy.

X
Trial Profile

A phase I study of AT9283 given as a 24 hour infusion on days 1 and 8 every three weeks in patients with advanced incurable malignancy.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AT 9283 (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 08 Feb 2017 Results of population model of AT9283 developed from the data of phase I trials of AT9283 (NCT00443976, NCT00522990, NCT00985868 and NCT01431664) published in the British Journal of Clinical Pharmacology.
    • 12 Nov 2010 Results from this trial will be presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics according to a Astex Therapeutics media release.
    • 26 Nov 2009 Planned end date changed from 1 Aug 2009 to 24 Nov 2009 as reported by National Cancer Institute of Canada record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top